RE:Lots of Buyouts Now in BiotechThis is what I've been reading in the financial press for 10 months or more. I guess that is why I get soo excited (and frustrated) about the (untapped) potential
The development of epigenetic platforms seems almost to becoming like software development with high hopes for treatments tailored to individual genetic situations...although the biotech is almost infinitely more complex than software. I believe that Princess Margret Hospital in Tornonto has achieved some positive results.
It certainly does look very positive for Zenith and RVX.
Toinv